PharmaTelevision - Stemgent: Fate, Obama and 74 new products

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Stemgent: Fate, Obama and 74 new products

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaVentures Business Review, Dr Fintan Walton caught up with Ian Ratcliffe, CEO of Stemgent, for an update on the company’s exciting past year. They discuss:

• induced Pluripotent cells

• the 74 products developed by Stemgent in the last year

• the importance of Barrack Obama’s changes to stem cell legislation

• Stemgent’s alliance with Fate Therapeutics and their Catalyst Programme: the consortium’s work to accelerate industrialisation of stem cell research

• Stemgent’s plans for the coming year to meet customer demand with unique, innovative products

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Origin and development of Stemgent

Fintan Walton:

Hello and welcome to PharmaVentures business review here at Bio in Atlanta. On this show I am pleased to have back Ian Ratcliffe who is the CEO of Stemgent. Last year you were here and we talked about your organization. Welcome back to PharmaVentures business review.

Ian Ratcliffe:

Thank you Fintan Walton and it's a great opportunity to update everybody about Stemgent.

Fintan Walton:

Okay.

Ian Ratcliffe:

Excited to be here.

Fintan Walton:

Okay, good. I know you have had an exciting year. Just remind our audience what--what Stemgent is about? What's the role of this organization?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Ian Ratcliffe

Chief Executive Officer

Ian Ratcliffe, President and CEO StemgentInc Boston, Massachusetts worked as Board Chairman at Enzymatics Inc and Chairman and Owner Enzymatics Inc and also as President at Upstate Executive Vice President Upstate.Chief Financial Officer, Chief Operating Officer and Executive Vice President of Sales, Marketing and Business Development Upstate and as President at Asterand plc Non-Executive Director Asterand plc President PBM Products LLC President of the Upstate Division Serologicals Corporation. Board Memberships and Affiliations Chairman of Board of Directors Enzymatics Inc Board Member Global Cell Solutions Inc Education M.B.A. Darden Graduate School of Business Administration at the University of Virginia first degree, Chemical Engineering University of Surrey Guilford.

Stemgent

Stemgent advances stem cell science by providing proprietary reagents and tools developed by some of the world's leading stem cell scientists. Stemgent's product offering has been specifically optimized for, and screened against, stem cells, and includes small molecules for pluripotency, self-renewal, and differentiation, viral-delivered transcription factors, matrices, cell lines, cytokines, antibodies, transfection reagents, and more. This unique product mix is designed to serve researchers who study stem cell biology and regenerative medicine, and those who use cells derived from stem cells as tools to advance their understanding of major diseases.